ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
US FDA accepts the NDA for Motif Bio’s iclaprim for ABSSSI treatment
pharmaceutical-technology
August 17, 2018The US Food & Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) by Motif Bio for iclaprim, which is a targeted, Gram-positive investigational antibiotic, indicated for the treatment of acute bacterial skin and skin struct -
Motif Bio’s antibiotic granted US priority review
pharmatimes
August 15, 2018US regulators have accepted for review a targeted, Gram-positive investigational antibiotic developed by UK biopharma Motif Bio for the treatment of acute bacterial skin and skin structure infections (ABSSSI). -
Cardiome Pharma’s Xydalba treatment for ABSSSI available in UK
pharmaceutical-technology
June 27, 2017Canadian pharmaceutical company Cardiome Pharma’s new intravenous (IV) antibiotic?for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults, known as?Xydalba (dalbavancin hydrochloride),?has been made available in the UK.
Pharma Sources Insight January 2025
